{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:15Z","timestamp":1793371515547,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00587-8","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:14:53Z","timestamp":1791184493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complex cardiac overlap: immune checkpoint inhibitor myocarditis in hypertrophic obstructive cardiomyopathy with subsequent NSTEMI"],"prefix":"10.1186","volume":"12","author":[{"given":"Ahmed","family":"Basuoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Makhlouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Dawelbeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"AlMalki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noof","family":"Alkharousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Albulushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Zribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zamzam","family":"Al-Hashami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"5","key":"587_CR1","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535.","journal-title":"JAMA Netw Open"},{"key":"587_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13:392.","journal-title":"Nat Commun"},{"issue":"5","key":"587_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854\u201368.","journal-title":"Cardiovasc Res"},{"issue":"13","key":"587_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","volume":"74","author":"S Ball","year":"2019","unstructured":"Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS, Fonarow GC, Lenihan DJ, Bhatt DL. Cardiovascular toxicities of immune checkpoint inhibitors. J Am Coll Cardiol. 2019;74(13):1714\u201327.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"587_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"12","key":"587_CR6","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.jacadv.2024.101374","volume":"3","author":"Y Tamura","year":"2024","unstructured":"Tamura Y. Evaluating troponin-based monitoring in patients undergoing immune checkpoint inhibitor therapy. JACC Adv. 2024;3(12):101374. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101374.","journal-title":"JACC Adv"},{"issue":"7","key":"587_CR7","doi-asserted-by":"publisher","first-page":"oyaf187","DOI":"10.1093\/oncolo\/oyaf187","volume":"30","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang L, Su Z, Lian X. Risk factors of immune checkpoint inhibitor-related cardiotoxicity: a scoping review. Oncologist. 2025;30(7):oyaf187. https:\/\/doi.org\/10.1093\/oncolo\/oyaf187.","journal-title":"Oncologist"},{"key":"587_CR8","doi-asserted-by":"publisher","first-page":"100345","DOI":"10.1016\/j.hmedic.2025.100345","volume":"14","author":"A Basuoni","year":"2025","unstructured":"Basuoni A, Makhlouf M, Dawelbeit W, Ahmed D, Al-Sharqi H, Al Farsi S, Al-Baimani K. When immunotherapy strikes the heart: a multimodal approach to immune checkpoint inhibitors\u2013induced myocarditis: a case series and literature review. Med Rep. 2025;14:100345. https:\/\/doi.org\/10.1016\/j.hmedic.2025.100345.","journal-title":"Med Rep"},{"issue":"10","key":"587_CR9","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with EHA, ESTRO and IC-OS. Eur Heart J Cardiovasc Imaging. 2022;23(10):e333\u2013465.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"587_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"587_CR11","first-page":"PO2000370","volume":"5","author":"N Aghel","year":"2021","unstructured":"Aghel N, Gustafson D, Di Meo A, et al. Recurrent myocarditis induced by immune checkpoint inhibitor treatment is accompanied by persistent inflammatory markers despite immunosuppressive treatment. JCO Precis Oncol. 2021;5:PO2000370.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"587_CR12","doi-asserted-by":"publisher","first-page":"e233585","DOI":"10.1136\/bcr-2019-233585","volume":"13","author":"B Kumar","year":"2020","unstructured":"Kumar B, Kodliwadmath A, Singh A, Duggal B. Acute adrenal insufficiency as a mysterious cause of shock following percutaneous coronary intervention: a cardiologist\u2019s nightmare. BMJ Case Rep. 2020;13(3):e233585.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"587_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cardfail.2024.10.186","volume":"31","author":"P Konstantinidis","year":"2025","unstructured":"Konstantinidis P, Bihag Z, Friligkou E, Burke-Martindale C, Smith E, Patel N, Weissler-Snir A, Jaiswal A. Safety and efficacy of mavacamten in adults with hypertrophic cardiomyopathy with obstruction: insights from a tertiary center. J Card Fail. 2025;31(1):253. https:\/\/doi.org\/10.1016\/j.cardfail.2024.10.186.","journal-title":"J Card Fail"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00587-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:03:00Z","timestamp":1791478980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00587-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00587-8","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"122"}}